Short versus standard treatment with pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: a randomised controlled trial.
Phase of Trial: Phase III
Latest Information Update: 29 Oct 2011
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Feb 2010 New trial record